New guidelines for prevention of oral mucositis (OM)
The organizations that publish internationally accepted guidelines for the treatment and prevention of oral mucositis (MASCC / ISOO) have for 2020 now revised their previous recommendations from 2013.
Of 114 articles published, 36 articles were reviewed which were considered to provide new information. The article mentions two articles published by odont.dr. Java Walladbegi with the product Cooral® System.
Both articles are part of Walladbegi's dissertation, which he defended earlier this year after 4 years as an industrial doctoral student employed by BrainCool AB. One of the co-authors of the systematic review article, that the new guidelines is based on, was Dr. Douglas Peterson who was the opponent at Walladbegi's dissertation. Dr. Peterson is the elect-to-be chair of the American Society of Clinical Oncology (ASCO) and FDA expert in the field.
The essence of the new recommendations is that prevention of OM with oral cryotherapy has been upgraded for hematology patients to the higher level of "recommendation". In addition, the recommendation for the prevention of OM with oral cryotherapy was confirmed in patients treated with 5-fluorouracil for the treatment of solid tumors.
BrainCool’s CEO Martin Waleij comments;
- It is with great satisfaction that we now note that the principle of Cooral® is recommended both for hematologically ill patients as well as for patients receiving 5-fluorouracil treatment for solid tumors.
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se
About BrainCool AB (publ)
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.